LiveWire Ergogenics (LVVV) AI Stock Analysis

• Market Cap: $151.13K
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): 33.3
• Beta (1Y): 65.05
• Revenue Growth: -67.23%
• EPS Growth: -66.67%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 1,511,245,200
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 50.21
• Enterprise Value/Revenue: 6.91
• Enterprise Value/Gross Profit: 7.09
• Enterprise Value/Ebitda: 8.58
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: ―

LiveWire Ergogenics has demonstrated strong financial performance with high profit margins and effective cash flow conversion. However, revenue volatility and moderate leverage pose risks. The lack of technical and earnings call data limits further insight, while the high P/E ratio suggests expectations for growth. Overall, the stock presents a moderate investment opportunity with potential risks and rewards.

LiveWire Ergogenics Business Overview & Revenue Model

Company Description

LiveWire Ergogenics Inc. focuses on acquiring, managing, and licensing special purpose real estate properties to produce handcrafted and organically grown cannabis products for medical and recreational adult-use in California. The company is based in Anaheim, California.

How the Company Makes Money

LiveWire Ergogenics makes money primarily through leasing and management of its cannabis-focused real estate properties. The company acquires properties specifically zoned and permitted for cannabis cultivation and production, enhancing their value by ensuring compliance with all relevant regulations. Revenue is generated from leasing these enhanced properties to licensed cannabis operators who pay rent for the use of these facilities. Additionally, LiveWire Ergogenics may benefit from revenue-sharing agreements with tenants, where they receive a percentage of the tenant's profits. The company may also engage in partnerships or joint ventures to further leverage its real estate assets and expand its revenue streams within the cannabis industry.

LiveWire Ergogenics Financial Statement Overview

Summary

Overall, LiveWire Ergogenics has shown a commendable transformation, with significant improvements in profitability and cash flow generation. High profit margins and improved operational efficiency are notable, although revenue growth volatility and moderate leverage remain concerns.

Income Statement

LiveWire Ergogenics has shown a strong improvement in its financial performance over the years. The company achieved a Gross Profit Margin of 97.59% in 2023, indicating efficient cost management. The Net Profit Margin also increased significantly to 56.40% in 2023, reflecting robust profitability. Revenue growth has been volatile, with a recent decline of 15.70% from 2022 to 2023, which might be a concern. However, the improved EBIT Margin of 50.79% and EBITDA Margin of 74.43% in 2023 underscore the company's enhanced operational efficiency.

Balance Sheet

The balance sheet of LiveWire Ergogenics reflects a mixed picture. The Debt-to-Equity Ratio is 1.07 in 2023, suggesting moderate leverage. The Return on Equity is notably high at 29.60%, indicating strong profitability relative to equity. The Equity Ratio, however, is 40.25%, indicating that a significant portion of assets is financed through equity. While the financial position has strengthened, the reliance on debt could pose risks if not managed properly.

Cash Flow

LiveWire Ergogenics has demonstrated improvement in cash flow generation. The Free Cash Flow grew significantly by 72.17% from 2022 to 2023, showcasing better cash management. The Operating Cash Flow to Net Income Ratio is 0.74, and the Free Cash Flow to Net Income Ratio is also 0.74, suggesting that earnings are effectively converting to cash. Despite these improvements, the company should continue focusing on maintaining cash flow stability.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.10M	1.63M	1.94M	851.20K	580.32K	344.23K
Gross Profit	1.07M	1.59M	1.80M	701.55K	376.51K	197.03K
EBITDA	884.44K	1.22M	1.07M	-2.68M	-302.00K	-515.00K
Net Income	610.31K	921.58K	684.12K	-3.43M	-1.60M	-1.78M
Balance Sheet
Total Assets	7.98M	7.74M	6.27M	4.52M	2.91M	3.32M
Cash, Cash Equivalents and Short-Term Investments	25.18K	27.87K	76.38K	199.95K	109.88K	53.73K
Total Debt	3.35M	3.34M	3.20M	2.85M	3.23M	2.43M
Total Liabilities	4.71M	4.62M	4.24M	3.61M	3.99M	3.10M
Stockholders Equity	3.26M	3.11M	2.03M	912.13K	-1.08M	373.96K
Cash Flow
Free Cash Flow	554.67K	682.37K	396.37K	-467.21K	315.33K	-790.06K
Operating Cash Flow	554.68K	682.37K	396.37K	-399.89K	356.16K	-778.86K
Investing Cash Flow	-608.74K	-857.40K	-1.20M	-930.51K	-874.12K	-644.16K
Financing Cash Flow	-46.89K	126.51K	684.50K	1.42M	627.84K	1.40M

LiveWire Ergogenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LVVV	64 Neutral	$151.13K	33.33	29.60%	―	-67.23%	-66.67%
CVSI	43 Neutral	$6.09M	-3.88	-133.37%	―	-5.50%	45.16%
MJNA	39 Underperform	$1.14M	―	-1.29%	―	-18.88%	87.50%
CANN	37 Underperform	$4.44M	-1.24	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%